Cux1 transcription factor is induced in inflammatory bowel disease and protects against experimental colitis†

2010 ◽  
Vol 16 (10) ◽  
pp. 1739-1750 ◽  
Author(s):  
Mathieu Darsigny ◽  
Stéphanie St-Jean ◽  
François Boudreau
Keyword(s):  
Inflammatory Bowel Disease ◽  
Transcription Factor ◽  
Bowel Disease ◽  
Experimental Colitis ◽  
Inflammatory Bowel

Mo1115 WHOLE-BLOOD EXPRESSION PROFILES IN INFLAMMATORY BOWEL DISEASE REVEAL TRANSCRIPTION FACTOR INVOLVEMENT

2020 ◽  
Vol 158 (6) ◽  
pp. S-792-S-793
Author(s):  
Jan Nowak ◽  
Alex Adams ◽  
Rahul Kalla ◽  
Daniel Bergemalm ◽  
Simen Vatn ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Transcription Factor ◽  
Bowel Disease ◽  
Whole Blood ◽  
Expression Profiles ◽  
Inflammatory Bowel

Changes in mucosal fatty acid profile in inflammatory bowel disease and in experimental colitis: a common response to bowel inflammation

1997 ◽  
Vol 16 (4) ◽  
pp. 177-183 ◽  
Author(s):  
F. Fernández-Bañares ◽  
M. Esteve-Comas ◽  
J. Mañé ◽  
E. Navarro ◽  
X. Bertrán ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Fatty Acid ◽  
Fatty Acid Profile ◽  
Bowel Disease ◽  
Experimental Colitis ◽  
Common Response ◽  
Inflammatory Bowel

scholarly journals The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease

2011 ◽  
Vol 12 (11) ◽  
pp. 1063-1070 ◽  
Author(s):  
Zhihua Liu ◽  
Jinwoo Lee ◽  
Scott Krummey ◽  
Wei Lu ◽  
Huaibin Cai ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Transcription Factor ◽  
Bowel Disease ◽  
Inflammatory Bowel ◽  
Transcription Factor Nfat

scholarly journals ErbB-1 experssion in experimental model of inflammatory bowel disease in rats

2004 ◽  
Vol 51 (2) ◽  
pp. 85-89 ◽  
Author(s):  
R. Trzcinski ◽  
M. Bry ◽  
W. Krajewska ◽  
M. Kulig ◽  
A. Dzyiki
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Growth Factor Receptor ◽  
Experimental Colitis ◽  
Altered Level ◽  
Pcr Products ◽  
Epidermal Growth ◽  
Inflammatory Bowel ◽  
Specific Symptoms

Background Ulcerative colitis (UC) and Crohn?s disease (CD) belong to inflammatory bowel disease (IBD). The etiology of IBD is still unknown. Therapy remains empiric or is used for the relief of specific symptoms. The erbB-1 oncogene coding epidermal growth factor receptor (EGFR) is typed as a prognostic marker in several benign and malignant tissues. The aim of our study was to examine the erbB-1 expression in experimental surgically performed model of IBD in rats and to find out if there is any correlation between severity of the intestinal inflammation and altered level of erbB-1 expression. After inducing an experimental colitis samples were taken from different parts of the intestine in all studied groups of rats for histopathology. ErbB-1 mRNA expression was estimated by RT-PCR. PCR products were separated on a 1,5% TBE-agarose gel and visualized with ethidium bromide. The integrated optical density (IOD) of electrophoretically separated amplification products was measured using a video densitometer and Gel-Pro 3.0 software. Nonparametrical statistical test has been used throughout in analyzing the results. Relative erbB-1 expression was determined by comparing to cyclophiline expression. Results Microscopic changes were similar to those observed in IBD. ErbB-1 expression was significantly higher in inflamed tissues of the bowel ( P=0.04 for the transverse colon and P=0.027 for the cecum). Significantly higher erbB-1 expression in inflamed tissues of the bowel suggests that EGFR overexpression may play a role in the pathogenesis of IBD. Overexpression of erbB-1 correlates with the severity of inflammation in bowel tissues.

scholarly journals PPARγin Inflammatory Bowel Disease

PPAR Research ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Vito Annese ◽  
Francesca Rogai ◽  
Alessia Settesoldi ◽  
Siro Bagnoli
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Potential Role ◽  
Intestinal Inflammation ◽  
Experimental Colitis ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Beneficial Effects ◽  
Inflammatory Bowel

Peroxisome proliferator-activated receptor gamma (PPARγ) is member of a family of nuclear receptors that interacts with nuclear proteins acting as coactivators and corepressors. The colon is a major tissue which expresses PPARγin epithelial cells and, to a lesser degree, in macrophages and lymphocytes and plays a role in the regulation of intestinal inflammation. Indeed, both natural and synthetic PPARγligands have beneficial effects in different models of experimental colitis, with possible implication in the therapy of inflammatory bowel disease (IBD). This paper will specifically focus on potential role of PPARγin the predisposition and physiopathology of IBD and will analyze its possible role in medical therapy.

Sign in / Sign up

Export Citation Format

Share Document